Synergy O
between O
interferon B
- I
gamma I
and O
tumor B
necrosis I
factor I
- I
alpha I
in O
transcriptional O
activation O
is O
mediated O
by O
cooperation O
between O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
and O
nuclear B
factor I
kappaB I
. O

A O
cDNA O
for O
human B
microfibril I
- I
associated I
glycoprotein I
- I
2 I
( O
MAGP B
- I
2 I
) O
was O
used O
to O
screen O
a O
human O
leukocyte O
genomic O
DNA O
library O
in O
EMBL O
- O
3 O
vector O
. O

Interaction O
of O
the O
v B
- I
rel I
protein I
with O
an O
NF B
- I
kappa I
B I
DNA I
binding I
site I
. O

A O
short O
conserved O
motif O
is O
required O
for O
repressor O
domain O
function O
in O
the O
myeloid O
- O
specific O
transcription O
factor O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
epsilon I
. O

Role O
of O
distinct O
mitogen B
- I
activated I
protein I
kinase I
pathways O
and O
cooperation O
between O
Ets B
- I
2 I
, O
ATF B
- I
2 I
, O
and O
Jun B
family I
members I
in O
human B
urokinase I
- I
type I
plasminogen I
activator I
gene I
induction O
by O
interleukin B
- I
1 I
and O
tetradecanoyl O
phorbol O
acetate O
. O

Paclitaxel O
caused O
a O
rapid O
and O
transient O
increase O
in O
c B
- I
Jun I
NH2 I
- I
terminal I
kinase I
( O
JNK B
) O
activity O
, O
a O
proposed O
mediator O
of O
stress O
activation O
pathways O
. O

Complete O
activation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
requires O
phosphorylation O
at O
both O
Y701 O
and O
a O
conserved O
PMS O
( O
727 O
) O
P O
sequence O
. O

Epstein B
- I
Barr I
virus I
nuclear I
antigen I
2 I
exerts O
its O
transactivating O
function O
through O
interaction O
with O
recombination B
signal I
binding I
protein I
RBP I
- I
J I
kappa I
, O
the O
homologue O
of O
Drosophila B
Suppressor I
of I
Hairless I
. O

By O
cloning O
genes O
encoding O
benzene O
- O
degradative O
enzymes O
, O
we O
found O
that O
strain O
JS150 O
also O
carries O
genes O
for O
a O
toluene B
/ I
benzene I
- I
2 I
- I
monooxygenase I
. O

The O
platelet B
membrane I
glycoprotein I
IIb I
/ I
IIIa I
receptor I
inhibitor O
abciximab O
is O
used O
for O
the O
treatment O
of O
patients O
undergoing O
high O
- O
risk O
percutaneous O
coronary O
interventions O
and O
is O
used O
in O
approximately O
one O
third O
of O
coronary O
interventions O
in O
the O
United O
States O
and O
a O
growing O
number O
of O
procedures O
in O
Europe O
. O

The O
prosomal B
RNA I
- I
binding I
protein I
p27K I
is O
a O
member O
of O
the O
alpha B
- I
type I
human I
prosomal I
gene I
family I
. O

The O
NrfC B
polypeptide I
, O
M B
( I
r I
) I
24 I
, I
567 I
, O
contains O
16 O
cysteine O
residues O
arranged O
in O
four O
clusters O
typical O
of O
the O
CooF B
super I
- I
family I
of O
non O
- O
haem O
iron O
- O
sulphur O
proteins O
. O

Its O
activity O
was O
twice O
that O
of O
a O
construct O
where O
the O
CAT B
gene I
was O
driven O
by O
the O
H B
- I
2Kb I
5 I
' I
enhancer I
region I
( O
H2TF1 B
/ O
KBF1 B
site O
) O
and O
comparable O
to O
that O
of O
pRSVCAT O
construct B
carrying I
the I
strong I
Rous I
sarcoma I
virus I
LTR I
enhancer I
. O

The O
predicted O
proteins O
show O
strong O
homology O
to O
an O
ABA B
- I
inducible I
glycine I
- I
rich I
protein I
from O
maize O
embryos O
and O
to O
the O
mammalian B
RNA I
- I
binding I
protein I
A1 I
of O
the O
heterogeneous O
nuclear O
ribonucleoprotein O
complex O
involved O
in O
pre O
- O
mRNA O
splicing O
. O

The O
deduced O
amino O
acid O
sequence O
of O
this O
open O
reading O
frame O
is O
significantly O
homologous O
to O
the O
HSV B
1 I
UL49 I
. I
5 I
gene I
product I
, O
and O
as O
with O
UL49 B
. I
5 I
, O
it O
contains O
a O
potential O
signal O
sequence O
and O
transmembrane O
domain O
characteristic O
of O
membrane O
- O
associated O
proteins O
. O

Siglec B
- I
9 I
is O
predicted O
to O
contain O
three O
extracellular O
immunoglobulin B
- I
like I
domains I
that O
comprise O
an O
N B
- I
terminal I
V I
- I
set I
domain I
and O
two O
C2 B
- I
set I
domains I
, O
a O
transmembrane O
region O
and O
a O
cytoplasmic O
tail O
containing O
two O
putative O
tyrosine O
- O
based O
signaling O
motifs O
. O

Whereas O
mutant B
6C4 I
specified O
a O
wild B
- I
type I
- I
size I
Pol I
protein I
, O
we O
detected O
no O
full B
- I
length I
Pol I
protein I
in O
7E4 O
- O
infected O
cell O
extracts O
. O

The O
hepatic O
isoform O
of O
6 B
- I
phosphofructo I
- I
2 I
- I
kinase I
/ O
fructose B
- I
2 I
, I
6 I
- I
bisphosphatase I
( O
PF2K B
/ O
Fru B
- I
2 I
, I
6 I
- I
BPase I
) O
is O
transcriptionally O
stimulated O
by O
glucocorticoids O
, O
whereas O
insulin B
blocks O
this O
stimulatory O
effect O
. O

The O
hepatic O
isoform O
of O
6 B
- I
phosphofructo I
- I
2 I
- I
kinase I
/ O
fructose B
- I
2 I
, I
6 I
- I
bisphosphatase I
( O
PF2K B
/ O
Fru B
- I
2 I
, I
6 I
- I
BPase I
) O
is O
transcriptionally O
stimulated O
by O
glucocorticoids O
, O
whereas O
insulin B
blocks O
this O
stimulatory O
effect O
. O

The O
hepatic O
isoform O
of O
6 B
- I
phosphofructo I
- I
2 I
- I
kinase I
/ O
fructose B
- I
2 I
, I
6 I
- I
bisphosphatase I
( O
PF2K B
/ O
Fru B
- I
2 I
, I
6 I
- I
BPase I
) O
is O
transcriptionally O
stimulated O
by O
glucocorticoids O
, O
whereas O
insulin B
blocks O
this O
stimulatory O
effect O
. O

Homodimers O
of O
RIP60 B
( O
replication B
initiation I
- I
region I
protein I
60 I
kDA I
) O
purified O
from O
nuclear O
extract O
bind O
two O
ATT O
- O
rich O
sites O
in O
oribeta O
and O
foster O
the O
formation O
of O
a O
twisted O
720 O
bp O
DNA O
loop O
in O
vitro O
. O

Initial O
computer O
based O
similarity O
searches O
identified O
human B
retinoblastoma I
binding I
protein I
1 I
( O
RBP B
- I
1 I
) O
, O
Drosophila B
melanogaster I
male I
specific I
lethal I
- I
3 I
( O
Msl B
- I
3 I
) O
, O
S B
. I
pombe I
altered I
polarity I
- I
13 I
( O
Alp13 B
) O
and O
S B
. I
cerevisiae I
Eaf3p I
, O
a O
component O
of O
the O
yeast B
NuA4 I
HAT B
complex O
( O
Galarneau O
et O
al O
. O
, O
2000 O
. O

Initial O
computer O
based O
similarity O
searches O
identified O
human B
retinoblastoma I
binding I
protein I
1 I
( O
RBP B
- I
1 I
) O
, O
Drosophila B
melanogaster I
male I
specific I
lethal I
- I
3 I
( O
Msl B
- I
3 I
) O
, O
S B
. I
pombe I
altered I
polarity I
- I
13 I
( O
Alp13 B
) O
and O
S B
. I
cerevisiae I
Eaf3p I
, O
a O
component O
of O
the O
yeast B
NuA4 I
HAT B
complex O
( O
Galarneau O
et O
al O
. O
, O
2000 O
. O

TNF B
- I
alpha I
effect O
was O
eliminated O
by O
a O
2 O
- O
bp O
substitution O
mutation O
in O
the O
NF B
- I
kappa I
B1 I
binding I
half I
site I
of O
the O
NF B
- I
kappa I
B I
cis I
element I
. O

Characterization O
of O
a O
nuclear B
deformed I
epidermal I
autoregulatory I
factor I
- I
1 I
( O
DEAF B
- I
1 I
) O
- O
related O
( O
NUDR B
) O
transcriptional O
regulator O
protein O
. O

An O
analysis O
of O
the O
c B
- I
kit I
5 I
' I
flanking I
region I
using O
the O
bacterial B
chloramphenicol I
acetyltransferase I
gene I
( O
CAT B
assay O
) O
in O
human O
erythroleukemia O
HEL O
cells O
, O
which O
express O
the O
endogenous O
c B
- I
kit I
mRNA I
at O
high O
levels O
, O
showed O
that O
a O
region O
from O
- O
180 O
to O
- O
22 O
is O
important O
for O
the O
expression O
of O
the O
c B
- I
kit I
gene I
. O

The O
Zn B
- I
15 I
DNA I
- I
binding I
domain I
comprises O
three O
zinc O
fingers O
separated O
by O
unusually O
long O
linker O
sequences O
that O
would O
be O
expected O
to O
interrupt O
specific O
DNA O
site O
recognition O
. O

The O
deduced O
amino O
acid O
sequence O
exhibits O
95 O
. O
3 O
and O
76 O
. O
1 O
% O
identity O
with O
the O
CAD B
sequences I
of I
hamster I
and I
Squalus I
acanthias I
. O

Basic B
helix I
- I
loop I
- I
helix I
proteins I
can O
act O
at O
the O
E O
- O
box O
within O
the O
serum O
response O
element O
of O
the O
c B
- I
fos I
promoter I
to O
influence O
hormone O
- O
induced O
promoter O
activation O
in O
Sertoli O
cells O
. O

Rewarding O
properties O
of O
methylphenidate O
: O
sensitization O
by O
prior O
exposure O
to O
the O
drug O
and O
effects O
of O
dopamine B
D1 I
- I
and I
D2 I
- I
receptor I
antagonists O
. O

Receptor B
- I
type I
serine I
/ I
threonine I
kinases I
( O
RSKs B
) O
have O
been O
organized O
into O
two O
distinct O
classes O
known O
as O
types O
I O
and O
II O
on O
the O
basis O
of O
sequence O
similarity O
. O

BCV B
mRNAs I
5 I
and I
5 I
- I
1 I
appear O
to O
be O
used O
for O
the O
synthesis O
of O
the O
12 O
. O
7 O
- O
and O
9 O
. O
5 O
- O
kDa O
proteins O
, O
respectively O
, O
which O
demonstrates O
a O
pattern O
of O
expression O
strikingly O
different O
from O
that O
utilized O
by O
MHV O
. O

Point O
mutations O
of O
Stat3 B
within O
the O
interacting O
domains O
blocked O
both O
physical O
interaction O
of O
Stat3 B
with O
c B
- I
Jun I
and O
their O
cooperation O
in O
IL B
- I
6 I
- O
induced O
transcription O
directed O
by O
the O
alpha B
( I
2 I
) I
- I
macroglobulin I
enhancer I
. O

Genetic O
analysis O
of O
the O
role O
of O
herpes B
simplex I
virus I
type I
1 I
glycoprotein I
K I
in O
infectious O
virus O
production O
and O
egress O
. O

The O
lipopolysaccharide O
- O
binding O
protein O
is O
a O
secretory B
class I
1 I
acute I
- I
phase I
protein I
whose O
gene O
is O
transcriptionally O
activated O
by O
APRF B
/ O
STAT B
/ I
3 I
and O
other O
cytokine O
- O
inducible O
nuclear O
proteins O
. O

These O
proteins O
, O
called O
variant B
surface I
glycoproteins I
( O
VSGs B
) O
, O
are O
expressed O
from O
a O
specific O
locus O
, O
the O
VSG B
gene I
expression I
site I
( I
ES I
) I
. O

A O
5789 B
- I
nucleotide I
- I
long I
EcoRI I
fragment I
from O
the O
genome O
of O
Thermotoga O
maritima O
, O
identified O
by O
cross O
- O
hybridization O
to O
L11 B
, O
L1 B
, O
L10 B
, O
and O
L12 B
ribosomal I
protein I
gene I
sequences I
from I
Escherichia I
coli I
, O
was O
cloned O
and O
sequenced O
. O

The O
S3 B
protein I
also O
contains O
a O
DNA O
repair O
activity O
, O
efficiently O
processing O
8 O
- O
oxoguanine O
residues O
in O
DNA O
via O
an O
N B
- I
glycosylase I
/ O
apurinic B
- I
apyrimidinic I
( I
AP I
) I
lyase I
activity O
. O

The O
pra2 B
gene I
encodes O
a O
pea B
( I
Pisum I
sativum I
) I
small I
GTPase I
belonging O
to O
the O
YPT B
/ O
rab B
family O
, O
and O
its O
expression O
is O
down O
- O
regulated O
by O
light O
, O
mediated O
by O
phytochrome B
. O

The O
DF3 B
/ O
MUC1 B
gene O
encodes O
a O
high B
molecular I
weight I
mucin I
- I
like I
glycoprotein I
which O
is O
overexpressed O
at O
the O
transcriptional O
level O
in O
the O
majority O
of O
human O
breast O
cancers O
. O

Sequence O
analysis O
and O
electrophoretic O
mobility O
shift O
experiments O
suggest O
that O
GnSE B
response I
elements I
interact O
, O
in O
these O
two O
regions O
, O
with O
GATA B
- I
and I
LIM I
- I
related I
factors I
, O
respectively O
. O

Genomic O
organization O
of O
the O
human B
multidrug I
resistance I
( I
MDR1 I
) I
gene I
and O
origin O
of O
P B
- I
glycoproteins I
. O

In O
src B
- O
transformed O
cells O
GAP B
forms O
heteromeric O
complexes O
, O
notably O
with O
a O
highly O
tyrosine O
phosphorylated O
62 B
- I
kDa I
protein I
( I
p62 I
) I
. O

Electrophoretic O
mobility O
- O
shift O
assays O
with O
nuclear O
extracts O
from O
COS O
- O
1 O
cells O
transfected O
with O
expression O
vectors O
for O
SMADs B
1 I
- I
5 I
indicate O
that O
SMAD3 B
forms O
a O
complex O
with O
a O
migration O
similar O
to O
that O
of O
the O
endogenous B
TGF I
- I
beta I
- I
specific I
complex I
observed O
in O
fibroblast O
extracts O
. O

Sequence O
analysis O
identifies O
a O
ras B
- I
associating I
( O
RA B
) O
- O
like O
domain O
in O
the O
N O
- O
termini O
of O
band B
4 I
. I
1 I
/ I
JEF I
domains I
and O
in O
the O
Grb7 B
/ I
10 I
/ I
14 I
adapter I
family I
. O

Sequence O
analysis O
identifies O
a O
ras B
- I
associating I
( O
RA B
) O
- O
like O
domain O
in O
the O
N O
- O
termini O
of O
band B
4 I
. I
1 I
/ I
JEF I
domains I
and O
in O
the O
Grb7 B
/ I
10 I
/ I
14 I
adapter I
family I
. O

Acetoacetate B
decarboxylase I
( O
ADC B
) O
( O
EC4 B
. I
1 I
. I
1 I
. I
4 I
) O
of O
Clostridium O
acetobutylicum O
DSM O
792 O
was O
purified O
to O
homogeneity O
, O
and O
its O
first O
25 O
N O
- O
terminal O
amino O
acids O
were O
determined O
. O

This O
region O
shows O
46 O
% O
identity O
with O
the O
calmodulin B
- I
binding I
region I
of O
rat B
brain I
Ca2 I
+ I
/ I
calmodulin I
- I
dependent I
protein I
kinase I
II I
and O
32 O
% O
identity O
with O
the O
equivalent O
region O
of O
chicken B
smooth I
muscle I
myosin I
light I
chain I
kinase I
. O

Repression O
of O
the O
herpes B
simplex I
virus I
1 I
alpha I
4 I
gene I
by O
its O
gene O
product O
( O
ICP4 B
) O
within O
the O
context O
of O
the O
viral O
genome O
is O
conditioned O
by O
the O
distance O
and O
stereoaxial O
alignment O
of O
the O
ICP4 B
DNA I
binding I
site I
relative O
to O
the O
TATA O
box O
. O

Extracellular B
regulated I
kinases I
( I
ERK I
) I
1 I
and O
ERK2 B
are O
authentic O
substrates O
for O
the O
dual B
- I
specificity I
protein I
- I
tyrosine I
phosphatase I
VHR I
. O

Such O
tetranucleotides O
are O
common O
in O
promoter O
regions O
, O
particularly O
in O
activating B
transcription I
factor I
/ O
cyclic B
AMP I
response I
element I
- I
binding I
protein I
( O
ATF B
/ O
CREB B
) O
and O
E O
- O
box O
motifs O
, O
suggesting O
that O
PIF B
may O
modulate O
the O
transcription O
of O
many O
genes O
. O

This O
communication O
presents O
two O
patients O
with O
clinically O
massive O
PE O
of O
recent O
onset O
( O
confirmed O
by O
lung O
perfusion O
scans O
) O
who O
were O
successfully O
treated O
with O
a O
single O
i O
. O
v O
. O
dose O
of O
30 O
mg O
of O
anisoylated B
lys I
- I
plasminogen I
streptokinase I
activator I
complex I
( O
APSAC B
, O
comparable O
to O
1 O
, O
500 O
, O
000 O
U O
of O
streptokinase B
) O
followed O
by O
systemic O
heparinization O
for O
7 O
days O
. O

The O
sequence O
of O
the O
gene O
upstream O
to O
the O
cap O
site O
contains O
characteristic O
RNA B
polymerase I
II I
promoter I
- I
binding I
sites I
: O
a O
putative O
TATA O
box O
at O
position O
- O
29 O
and O
a O
Sp B
1 I
binding I
site I
( O
GGGGCGGAGA O
) O
at O
position O
- O
48 O
. O

Desensitization O
of O
the O
growth B
hormone I
- O
induced O
Janus B
kinase I
2 I
( O
Jak B
2 I
) O
/ O
signal B
transducer I
and I
activator I
of I
transcription I
5 I
( O
Stat5 B
) O
- O
signaling O
pathway O
requires O
protein O
synthesis O
and O
phospholipase B
C I
. O

To O
increase O
the O
number O
of O
circulating O
polymorphonuclear O
neutrophils O
, O
the O
patient O
was O
treated O
with O
recombinant O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
at O
a O
dose O
of O
2 O
micrograms O
protein O
/ O
kg O
bodyweight O
s O
. O
c O
. O
/ O
12 O
h O
. O

By O
using O
methanol O
- O
0 O
. O
15 O
M O
borate O
buffer O
of O
pH O
8 O
. O
0 O
, O
cate B
- I
chol I
- I
O I
- I
methyltransferase I
activity O
might O
be O
assayed O
. O

Gel O
shift O
and O
southwestern O
experiments O
revealed O
nuclear O
proteins O
of O
43 O
kDa O
and O
30 O
kDa O
in O
GC O
and O
fish O
cells O
, O
respectively O
, O
that O
bind O
specifically O
to O
the O
tGH B
CRE O
, O
suggesting O
the O
involvement O
of O
CRE B
- I
binding I
- I
protein I
/ O
activating B
- I
transcription I
- I
factor I
- I
l I
- O
related O
peptides O
in O
cAMP O
response O
. O

On O
the O
basis O
of O
experiments O
with O
mutant O
virus O
and O
transfection O
with O
isolated O
genes O
, O
the O
herpes B
simplex I
virus I
immediate I
- I
early I
gene I
product O
ICP4 B
is O
known O
to O
positively O
regulate O
the O
transcription O
of O
viral B
early I
and I
late I
genes I
and O
negatively O
regulate O
expression O
from O
its O
own O
promoter O
. O

These O
results O
suggest O
an O
essential O
role O
of O
the O
binding O
of O
HNF B
- I
4 I
and O
/ O
or O
HNF B
- I
4 I
- I
related I
nuclear I
factors I
to O
the O
6 O
beta O
A O
- O
A O
site O
on O
the O
basal O
transcriptional O
activation O
of O
the O
CYP3A2 B
gene I
in O
liver O
cells O
. O

The O
cyclin B
- I
dependent I
kinase I
Cdk2 B
associates O
with O
cyclins B
A I
, I
D I
, I
and I
E I
and O
has O
been O
implicated O
in O
the O
control O
of O
the O
G1 O
to O
S O
phase O
transition O
in O
mammals O
. O

The O
amino B
- I
terminal I
gag I
- I
encoded I
region I
of O
P140gag B
- O
fps B
contains O
a O
phosphotyrosine O
residue O
in O
addition O
to O
normal O
gag B
phosphorylation O
sites O
. O

Cotransfection O
of O
a O
junB B
stimulated O
the O
basal O
activity O
of O
the O
alpha B
2 I
( I
I I
) I
collagen I
promoter I
93 O
- O
fold O
, O
respectively O
. O

A O
new O
myocyte B
- I
specific I
enhancer I
- I
binding I
factor I
that O
recognizes O
a O
conserved O
element O
associated O
with O
multiple O
muscle O
- O
specific O
genes O
. O

Activation O
of O
the O
cytotactin B
promoter I
by O
the O
homeobox B
- I
containing I
gene I
Evx I
- I
1 I
. O

The O
delayed O
activation O
of O
the O
prostaglandin B
G I
/ I
H I
synthase I
- I
2 I
promoter O
in O
bovine O
granulosa O
cells O
is O
associated O
with O
down O
- O
regulation O
of O
truncated O
upstream B
stimulatory I
factor I
- I
2 I
. O

Transcriptional O
activation O
of O
the O
proopiomelanocortin B
gene I
by O
cyclic B
AMP I
- I
responsive I
element I
binding I
protein I
. O

Historically O
, O
Cyps B
were O
first O
identified O
by O
their O
ability O
to O
bind O
the O
immunosuppressive O
agent O
cyclosporin O
A O
( O
CsA O
) O
with O
high O
affinity O
; O
they O
later O
were O
found O
to O
have O
peptidyl B
- I
prolyl I
cis I
- I
trans I
isomerase I
( O
PPIase B
) O
activity O
, O
which O
catalyzes O
the O
folding O
of O
oligopeptides O
at O
proline O
- O
peptide O
bonds O
in O
vitro O
and O
may O
be O
important O
for O
protein O
folding O
in O
vivo O
. O

Hematopoietic B
progenitor I
kinase I
1 I
( O
HPK1 B
) O
is O
a O
member O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
kinase I
( O
MAP4K B
) O
family O
and O
an O
upstream O
activator O
of O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
signaling O
cascade O
. O

Transient O
- O
expression O
assay O
analysis O
of O
subclones O
of O
pPstI O
- O
G O
localized O
the O
trans O
- O
active O
factor O
to O
a O
3 B
. I
0 I
- I
kilobase I
XbaI I
fragment I
. O

MGF B
is O
a O
novel O
member O
of O
the O
cytokine B
- I
regulated I
transcription I
factor I
gene I
family I
. O

A O
new O
B O
- O
cell O
- O
specific O
enhancer O
element O
has O
been O
identified O
3 O
' O
of O
E4 B
and O
the O
octamerlike O
motifs O
in O
the O
human B
immunoglobulin I
heavy I
- I
chain I
gene I
enhancer I
. O

Although O
cDNA O
encoding O
a O
human B
phagocyte I
formyl I
peptide I
- I
binding I
protein I
has O
been O
reported O
recently O
( O
Boulay O
, O
F O
. O
, O
Tardif O
, O
M O
. O
, O
Brouchon O
, O
L O
. O
, O
and O
Vignais O
, O
P O
. O

Three O
RasV12 B
mutants I
( O
S35 B
, O
G37 B
, O
and O
C40 B
) O
which O
differ O
by O
their O
ability O
to O
bind O
to O
Ras B
effectors I
( O
Raf B
, O
Ral B
- I
GEFs I
, O
and O
the O
p110 B
subunit I
of I
PI I
3 I
- I
kinase I
, O
respectively O
) O
were O
able O
to O
induce O
sustained O
NR O
cell O
proliferation O
, O
although O
none O
of O
these O
mutants O
was O
reported O
to O
transform O
NIH O
3T3 O
cells O
. O

The O
point O
mutation O
Asp O
- O
316 O
- O
- O
> O
Asn O
in O
the O
C O
- O
terminus O
of O
p38 B
, O
analogous O
to O
the O
ERK2 B
( O
extracellular B
- I
signal I
- I
regulated I
kinase I
2 I
) O
sevenmaker B
mutation O
, O
dramatically O
decreases O
its O
binding O
to O
MKP B
- I
1 I
and O
substantially O
compromises O
its O
stimulatory O
effect O
on O
the O
catalytic O
activity O
of O
this O
phosphatase O
. O

Incidence O
of O
beta O
- O
thalassemia O
carriers O
and O
those O
deficient O
in O
erythrocyte B
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
in O
the O
greater O
Buenos O
Aires O
area O

We O
also O
show O
that O
the O
products O
of O
both O
the O
GIY B
- I
YIG I
ORF O
and O
the O
non O
- O
canonical O
LAGLI B
- I
DADG I
- I
GIY I
- I
YIG I
ORF O
, O
which O
is O
generated O
by O
its O
integration O
, O
have O
endonuclease O
activities O
which O
recognize O
and O
cut O
the O
insertion O
site O
of O
the O
optional O
sequence O
. O

UVB O
- O
induced O
association O
of O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
1 I
/ O
TNF B
receptor I
- I
associated I
factor I
- I
2 I
mediates O
activation O
of O
Rel B
proteins I
. O

A B
. I
thaliana I
cystathionine I
beta I
- I
lyase I
exhibits O
22 O
% O
sequence O
identity O
with O
the O
E O
. O
coli O
corresponding O
enzyme O
and O
contains O
a O
70 O
amino O
acid O
N O
- O
terminal O
additional O
sequence O
compared O
with O
the O
bacterial O
protein O
. O

Csk B
( O
C B
- I
terminal I
Src I
kinase I
) O
is O
a O
protein B
tyrosine I
kinase I
that O
phosphorylates O
Src B
family I
member I
C I
- I
terminal I
tails I
, O
resulting O
in O
downregulation O
of O
Src B
family O
members O
. O

Human B
CD38 I
, O
a O
leukocyte O
receptor O
and O
ectoenzyme O
, O
is O
a O
member O
of O
a O
novel O
eukaryotic O
gene O
family O
of O
nicotinamide B
adenine I
dinucleotide I
+ I
- I
converting I
enzymes I
: O
extensive O
structural O
homology O
with O
the O
genes O
for O
murine B
bone I
marrow I
stromal I
cell I
antigen I
1 I
and O
aplysian B
ADP I
- I
ribosyl I
cyclase I
. O

Human B
CD38 I
, O
a O
leukocyte O
receptor O
and O
ectoenzyme O
, O
is O
a O
member O
of O
a O
novel O
eukaryotic O
gene O
family O
of O
nicotinamide B
adenine I
dinucleotide I
+ I
- I
converting I
enzymes I
: O
extensive O
structural O
homology O
with O
the O
genes O
for O
murine B
bone I
marrow I
stromal I
cell I
antigen I
1 I
and O
aplysian B
ADP I
- I
ribosyl I
cyclase I
. O

This O
complex O
was O
eliminated O
by O
mutation O
of O
either O
half O
- O
site O
, O
and O
it O
was O
supershifted O
by O
antibodies O
against O
chicken B
ovalbumin I
upstream I
promoter I
- I
transcription I
factor I
( O
COUP B
- I
TF I
) O
. O

fz B
- I
1 I
and I
- I
2 I
mRNA I
levels O
were O
greater O
in O
neonatal O
than O
in O
corresponding O
adult O
tissues O
. O

Sequence O
comparisons O
reveal O
that O
the O
P B
. I
woesei I
GTP I
- I
binding I
protein I
is O
strikingly O
related O
in O
sequence O
to O
eubacterial B
FtsZ I
and O
is O
marginally O
more O
similar O
to O
eukaryotic B
tubulins I
than O
are O
bacterial B
FtsZ I
proteins I
. O

In O
this O
work O
, O
we O
have O
used O
Xenopus O
oocyte O
maturation O
as O
a O
read O
- O
out O
for O
examining O
the O
ability O
of O
the O
neu B
tyrosine B
kinase I
( O
p185neu B
) O
to O
participate O
with O
the O
epidermal B
growth I
factor I
( I
EGF I
) I
receptor I
in O
a O
common O
signal O
transduction O
pathway O
. O

Northern O
blot O
analysis O
confirmed O
that O
ADAMTS B
- I
1 I
was O
up O
- O
regulated O
in O
both O
metaphyseal O
( O
14 O
- O
to O
35 O
- O
fold O
) O
and O
diaphyseal O
( O
4 O
. O
2 O
- O
fold O
) O
bone O
1 O
h O
after O
PTH B
- I
( I
1 I
- I
38 I
) I
injection O
and O
returned O
to O
control O
levels O
by O
24 O
h O
. O

Sequence O
analysis O
revealed O
that O
Hv B
- I
p68 I
belongs O
to O
the O
large O
family O
of O
FAD B
- I
dependent I
glucose I
methanol I
choline I
oxidoreductases I
and O
that O
it O
shares O
significant O
sequence O
identity O
( O
> O
67 O
% O
) O
with O
the O
alcohol B
oxidases I
of O
the O
methylotrophic O
yeasts O
. O

Two O
genes O
( O
ptsI B
and O
ptsA B
) O
that O
encode O
homologues O
of O
the O
energy O
coupling O
Enzyme B
I I
of O
the O
phosphoenolpyruvate B
- I
dependent I
sugar I
- I
transporting I
phosphotransferase I
system O
( O
PTS O
) O
have O
previously O
been O
identified O
on O
the O
Escherichia O
coli O
chromosome O
. O

Characterization O
of O
human B
activating I
transcription I
factor I
4 I
, O
a O
transcriptional O
activator O
that O
interacts O
with O
multiple O
domains O
of O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
( O
CREB B
) O
- O
binding O
protein O
. O

Using O
a O
set O
of O
sera O
for O
which O
full O
chlamydial O
micro O
- O
immunofluorescence O
results O
suggested O
a O
clear O
diagnosis O
, O
we O
have O
evaluated O
the O
Chlamydia O
Spot O
- O
IF O
test O
( O
bioMerieux O
) O
, O
which O
allows O
a O
comparison O
of O
titres O
to O
Chlamydia B
trachomatis I
and I
C I
. I
psittaci I
antigens I
. O

The O
non B
- I
major I
histocompatibility I
complex I
( O
MHC B
) O
- O
encoded O
CD1 B
family I
has O
recently O
emerged O
as O
a O
new O
antigen O
- O
presenting O
system O
that O
is O
distinct O
from O
either O
MHC B
class I
I I
or I
class I
II I
molecules I
. O

After O
birth O
, O
there O
was O
a O
significantly O
higher O
increase O
of O
IgA B
and O
IgM B
anti I
- I
M I
. I
leprae I
antibody I
activity O
in O
sera O
taken O
3 O
- O
6 O
months O
after O
birth O
from O
babies O
of O
Group O
1 O
compared O
to O
Group O
2 O
, O
but O
the O
IgA B
and O
IgM B
activity O
in O
sera O
taken O
after O
6 O
months O
of O
age O
showed O
the O
same O
increase O
in O
the O
two O
groups O
. O

This O
result O
, O
together O
with O
the O
fact O
that O
unrearranged B
V I
kappa I
genes I
are O
transcriptionally O
silent O
, O
suggests O
that O
structural O
features O
of O
both O
the O
V B
kappa I
and O
C B
kappa I
loci I
contribute O
to O
the O
overall O
transcriptional O
efficiency O
of O
a O
rearranged B
V I
kappa I
- I
C I
kappa I
gene I
. O

A O
positive O
FTA B
- I
ABS I
- I
19S I
- I
IgM I
test O
indicates O
the O
necessity O
of O
treatment O
. O

These O
data O
suggest O
that O
the O
fibrinogen B
gamma I
chain I
region I
Gly190 I
- I
Val202 I
functions O
as O
a O
minimal O
recognition O
sequence O
for O
the O
leukocyte O
integrin O
CD11b B
/ O
CD18 B
. O

A O
selectable O
marker O
for O
transformation O
was O
constructed O
by O
transcriptional O
fusion O
of O
a O
Ustilago B
maydis I
heat I
shock I
gene I
promoter I
with O
the O
hygromycin B
B I
phosphotransferase I
gene I
of I
Escherichia I
coli I
. O

The O
translational O
product O
of O
UL26 B
. I
5 I
is O
infected B
- I
cell I
protein I
35c I
, I
d I
( O
ICP35c B
, I
d I
) O
( O
F O
. O

PtdIns B
( I
4 I
, I
5 I
) I
P2 I
synthesis O
, O
on O
the O
other O
hand O
, O
is O
only O
moderately O
affected O
even O
in O
fab1Delta B
mutants I
. O

Transcriptional O
modulation O
of O
the O
anti B
- I
apoptotic I
protein I
BCL I
- I
XL I
by O
the O
paired B
box I
transcription I
factors I
PAX3 B
and O
PAX3 B
/ O
FKHR B
. O

The O
evolutionary O
significance O
of O
the O
similarities O
of O
intron O
secondary O
structures O
and O
open O
reading O
frames O
of O
the O
ND3 B
, I
4 I
and I
ATPase I
6 I
genes I
is O
discussed O
, O
including O
the O
possible O
separate O
evolution O
of O
structural O
and O
coding O
sequences O
. O

Nuclear O
proteins O
bound O
the O
cad B
+ I
55 I
/ I
+ I
75 I
element I
in O
a O
cell O
cycle O
- O
dependent O
manner O
in O
electromobility O
shift O
assays O
; O
antibodies O
specific O
to O
USF B
and O
Max B
blocked O
the O
DNA O
- O
binding O
activity O
of O
different O
growth O
- O
regulated O
protein O
- O
DNA O
complexes O
. O

gp170 B
is O
generated O
by O
an O
alternatively O
spliced O
Env B
mRNA I
using O
a O
splice O
donor O
and O
splice O
acceptor O
pair O
localized O
within O
the O
env B
open I
reading I
frame I
( I
ORF I
) I
, O
which O
is O
normally O
used O
to O
generate O
Bell B
and O
Bet B
transcripts I
derived O
from O
the O
internal O
promoter O
within O
the O
env B
ORF I
. O

In O
marked O
contrast O
to O
the O
previously O
published O
human B
CD6 I
sequence I
, O
the O
mouse O
sequence O
predicts O
a O
long O
cytoplasmic O
tail O
that O
is O
not O
closely O
related O
to O
other O
proteins O
and O
possesses O
two O
proline O
- O
rich O
motifs O
containing O
the O
SH3 B
- I
domain I
binding I
consensus I
sequence I
, O
three O
protein B
kinase I
C I
phosphorylation I
site I
motifs I
, O
nine O
casein B
kinase I
- I
2 I
phosphorylation I
site I
motifs I
, O
and O
a O
serine O
- O
threonine O
- O
rich O
motif O
repeated O
three O
times O
. O

These O
include O
the O
genes O
, O
undefined B
1 I
( O
UD1 B
) O
, O
UD2 B
, O
and O
UD3 B
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B
gene I
encoding O
a O
new O
Kruppel B
- I
like I
putative I
transcription I
factor I
, O
the O
fly O
homologues O
of O
the O
mammalian B
mitochondrial I
trifunctional I
enzyme I
( O
thiolase B
) O
, O
and O
the O
TAR B
DNA I
- I
binding I
protein I
- I
43 I
( O
TBPH B
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B
4 I
superfamily I
( O
TM4SF B
) O
gene O
, O
a O
new O
homeodomain B
gene I
, O
and O
a O
gene O
coding O
for O

TRAF2 B
has O
previously O
been O
demonstrated O
to O
activate O
both O
transcription O
factor O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
and O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
/ O
stress B
- I
activated I
protein I
kinase I
( O
JNK B
/ O
SAPK B
) O
pathway O
, O
which O
in O
turn O
stimulates O
transcription B
factor I
activating I
protein I
1 I
( O
AP1 B
) O
mainly O
via O
phosphorylation O
of O
the O
c B
- I
Jun I
component O
. O

The O
sequences O
at O
- O
10 O
and O
- O
35 O
relative O
to O
the O
transcriptional O
starting O
site O
showed O
55 O
% O
homology O
with O
the O
consensus O
sequences O
of O
the O
Escherichia B
coli I
sigma I
70 I
- I
type I
promoter I
. O

Decidual B
/ I
trophoblast I
prolactin I
- I
related I
protein I
: O
characterization O
of O
gene O
structure O
and O
cell O
- O
specific O
expression O
. O

LCCH1 B
was O
identical O
to O
the O
Rdl B
gene I
, O
a O
known O
GABA B
receptor I
subunit I
gene I
from O
D O
. O
melanogaster O
, O
whereas O
LCCH2 B
and O
LCCH3 B
were O
novel O
D O
. O
melanogaster O
sequences O
that O
exhibited O
structural O
similarity O
to O
other O
members O
of O
the O
ligand B
- I
gated I
chloride I
channel I
gene I
family I
. O

